News

 

NEWS

Amarantus Inks Alzheimer’s Biomarker Test Deal with Anavex

Amarantus BioScience Holdings today said that it has signed a deal to provide biomarker test services to Anavex Life Sciences for studies of that firm’s Alzheimer’s drug candidate. Under the deal, Amarantus will use its LymPro Test to evaluate the pharmacodynamic effect of Anavex 2-73 and Anavex Plus on the expression of the biomarker CD69 in specific sub-populations of peripheral […]

Read more

Senior Management Changes at Assembly Biosciences

Co-founder Derek Small succeeds Russell H. Ellison, MD, as CEO, as had been agreed in the merger last year that established Assembly. Small remains President; current director William Ringo has been named non-executive Chairman; and David J. Barrett has been named Chief Operating Officer, in addition to his current role as Chief Financial Officer. Read the press release at Globe […]

Read more

John Mulcahy, SiteOne Therapeutics

Developing a non-addictive painkiller to compete with opiates Mission Bay Capital portfolio company John Mulcahy is co-founder and vice-president of research at SiteOne Therapeutics, a company developing a non-addictive oral replacement for narcotic pain medications such as oxycodone and Vicodin. SiteOne recently won a $1.4M SBIR grant and raised $1.5M in private funding, including an investment by QB3’s fund Mission […]

Read more

Colleen Cutcliffe, Whole Biome

Improving human health by sequencing and analyzing the microbiome and developing targeted therapies Colleen Cutcliffe is co-founder and CEO of Whole Biome, a company working with the Mayo Clinic and others to analyze the microbiome—the community of microorganisms that lives on and in our bodies—and to develop therapies that use the microbiome to improve human health. Whole Biome, which has […]

Read more

Uri Lopatin, Assembly Biosciences

Targeting the hepatitis B virus Ramen to reverse merger in under two years. Uri Lopatin co-founded Assembly Pharmaceuticals in 2012, first working from home and then riding his bicycle to our incubator. At one point he literally ate ramen noodles for two months straight. But less than two years later, his startup merged with Ventrus Biosciences to form Assembly Biosciences, […]

Read more

MedGenome keen to team-up with state govts

MedGenome is looking to partner with the state governments in the country to offer its OncoMD, a cancer analytics platform with information on over 1.2 million cancer mutations allowing accurate interpretation of genomic variations. Currently in India there are cancer camps conducted in rural areas and district hospitals. In Karnataka the state government owned Kidwai Memorial Institute of Oncology has […]

Read more

Innovation in fixed-dose combos: HIV/AIDS therapeutics edition

The FDA has published guidance to support the submission process for companies developing fixed-dose combinations (FDCs) for the treatment of HIV patients. According to this guidance, “FDCs are essential for the treatment of HIV/AIDS…They are consistent with the goal of HIV therapy—to maximally and durably suppress virus to allow the recovery of the immune system and reduce the emergence of HIV resistance.” However, […]

Read more

It’s free! QB3 inks equipment donation deal for biomed startups

It’s free! QB3 inks equipment donation deal for biomed startups One of the lures of the University of California’s QB3 incubator network for life sciences startups is access to the same core facilities — centralized sites with million-dollar pieces of equipment — used by top-flight medical researchers. Now QB3 and partner American Laboratory Trading Inc. believe they’ve found a way […]

Read more
Page 8 of 8« First...45678

Upcoming Event

  • Reaction before action: new approaches to biomineralization-associated diseases

    12:30-13:30
    10/19/2017
    Daniel Laser, PhD CEO and Co-Founder, Applaud Medical RSVP Applaud Medical is a three-year-old company developing treatments for biomineralization-related diseases. Applaud's products use violent physical effects like cavitation and shock waves to achieve a therapeutic effect, while sparing non-targeted tissue through precise chemical targeting. Applaud's lead product, for low-invasiveness treatment of kidney stones, is currently in clinical trials in Gujarat, India. This seminar will cover technical aspects of combining chemical reactions with mechanical action in both Applaud's products and in a range of other drugs and devices, along with a brief discussion of key commercialization considerations for this uniquely promising product category. About Daniel Laser Daniel Laser is Chief Executive Officer and co-founder of Applaud Medical. Dan also founded Wave 80 Biosciences, a pioneer in detecting HIV during the high-transmission-risk earliest phase of infection, when the immune response is insufficiently advanced for antibody-based methods. He has served as board member or advisor to drug and device companies in fields ranging from autoimmune disease to ophthalmology to cancer. Dan got his start in the medical device field working on haptic feedback for telerobotic surgery systems. Dan holds a Ph.D. in mechanical engineering from Stanford University, where he was a Semiconductor Research Corporation Graduate Fellow. While at Stanford, he was also a MacArthur Affiliate at Stanford’s Center for International Security and Cooperation, developing mathematical models for protecting against threats involving weaponized pathogens.

Address

953 Indiana St., San Francisco, CA 94107
Tel: (415)-347-8287
Map

Sign-Up for our Newsletter